This week, the FDA decided in a 10:7 vote to approve Provention Bio’s teplizumab, a drug that could delay the onset of type 1 diabetes for up to two years for high-risk individuals. Recent clinical trial data suggest…
COVID Fears Kept One in Five People With Diabetes Away From the Doctor During Pandemic
Results released by dQ&A and the…
Breaking Data on COVID-19 Vaccination Rates Among People with Diabetes
While people with diabetes have been prioritized for vaccine eligibility…
Major Pharmacies Failing to Meet the Needs of People With Diabetes, According to National dQ&A® Survey
There is a wide variation in quality…
“A Day You Will Never Forget”
Being diagnosed with diabetes can be a life-changing experience. To better understand the diagnosis experience, we reached out…
Presentation to Congressional Diabetes Caucus
dQ&A and the ADA presented data to the Congressional Diabetes Caucus on COVID-19’s impact…
COVID-19: Resurgence in Fears for Diabetes Community in the United States
In previous waves, fears were trending downwards…
Diabetes News of Note: Connected Pens
Medtronic recently announced that they acquired Companion Medical, manufacturer of the InPen…
New Data Highlights Severe Health and Economic Impact of Pandemic on Millions Living with Diabetes
Research details the economic strains…
COVID-19: Challenges Remain, Even as States Reopen
People with diabetes are still extremely concerned about their health and finances…
